News

AbstractBACKGROUND Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare and fatal cardiomyopathy resulting from myocardial deposition of misfolded transthyretin…

AbstractBackground: Acoramidis, an oral transthyretin stabilizer that achieves near-complete (≥90%) transthyretin stabilization, demonstrated significant clinical…

AbstractCardiac amyloidosis (CA) is a progressive infiltrative cardiomyopathy most commonly caused by transthyretin (ATTR) or immunoglobulin light chain (AL)…

There were no safety findings associated with vitamin A deficiency following treatment with patisiran or vutrisiran in patients with transthyretin (TTR) amyloidosis…

Citi sees the risk-reward balance as favourable for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) ahead of headline results from a pivotal trial of its heart drug…

At age 86, Jack Nicklaus no longer strolls the fairways with a bounce in his step, but age is not the only specific factor in the Golden Bear's slowdown.Nicklaus…

Transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive disease characterized by the accumulation of misfolded transthyretin amyloid proteins in the…

The Key Hereditary Transthyretin Amyloidosis Companies in the market include - Alnylam Pharmaceuticals, Ionis Pharmaceuticals, AstraZeneca, Pfizer, Intellia…

More recent clinical trials also show less advanced disease in patientsPeople with transthyretin amyloid cardiomyopathy (ATTR-CM) enrolled in more recent…

AbstractIntroductionTimely diagnosis and treatment are essential for improving outcomes and quality of life in patients with transthyretin (ATTR) amyloidosis. Early…